Lung Cancer | Specialty

FDA Approval Insights: Ramucirumab/Erlotinib in EGFR+ Metastatic NSCLC

July 6th 2020

Edgardo S. Santos, MD, discusses the data that led to the approval of the combination of ramucirumab and erlotinib in EGFR-mutant metastatic non–small cell lung cancer and shared his thoughts on its utility in the frontline setting.

Review of Treatment for Limited-Stage Small-Cell Lung Cancer

July 6th 2020

Second- and Third-Line Treatment for ES-SCLC

July 6th 2020

Role of PCI Versus Brain MRI Surveillance in ES-SCLC

July 6th 2020

Expert Approaches to Treating Extensive Stage SCLC

July 6th 2020

KEYNOTE-604 and ECOG-ACRIN 5161 Trials for ES-SCLC

July 6th 2020

IMpower133 and CASPIAN Trials for Extensive Stage SCLC

July 6th 2020

ASCO 2020 Ushers in a Number of New Targeted Therapy Developments in NSCLC

July 5th 2020

Paul A. Bunn, Jr, MD, discusses how fam-trastuzumab deruxtecan-nxki could provide patients with metastatic non–small cell lung cancer who harbor HER2 exon 20 insertion mutations and high HER2 expression a more specific and less toxic treatment compared with platinum doublet chemotherapy.

Brahmer Highlights Practice-Changing Data in HER2-Mutated NSCLC

July 3rd 2020

Julie R. Brahmer, MD, discusses the details of the DESTINY-Lung01 trial, as well as remaining questions that could be answered with further research.

Talking KRAS-Targeted Therapy in NSCLC With Dr. Drilon

July 2nd 2020

In our exclusive interview, Alexander Drilon, MD, discusses some of the historical challenges of targeting KRAS and provided perspective on available and anticipated data with AMG 510 in non–small cell lung cancer.

Dr. Peters Discusses Ongoing Research With Trastuzumab Deruxtecan in NSCLC

July 2nd 2020

Solange Peters, MD,​ PhD, discusses ongoing research with ​fam-trastuzumab deruxtecan​-nxki (Enhertu; ​DS-8201) in patients with HER2-mutated non–small cell lung cancer.

Capmatinib Approved in Japan for METex14-Altered Advanced NSCLC

June 29th 2020

The Japanese Ministry of Health, Labor, and Welfare has approved capmatinib for patients with MET exon 14 skipping mutation–positive advanced and/or recurrent unresectable non–small cell lung cancer.

DESTINY-Lung01 Data Position Trastuzumab Deruxtecan as Next Oncogene-Driven Therapy in NSCLC

June 29th 2020

Nathan A. Pennell, MD, PhD, discusses the significance of findings from the DESTINY-Lung01 trial in non–small cell lung cancer.

Liu Lends Insight on Highlights From ASCO 2020 in Lung Cancer

June 25th 2020

A number of influential clinical trials were presented during the 2020 ASCO Virtual Scientific Program, 8 of which Stephen Liu, MD, discusses in depth in a virtual presentation during the 2020 ASCO Direct Highlights webcast.

Nivolumab/Ipilimumab Demonstrates OS Benefit in Advanced NSCLC With Brain Metastases

June 24th 2020

The combination of nivolumab and ipilimumab provided similar clinical benefit to that of chemotherapy when given as a frontline treatment for patients with advanced non–small cell lung cancer who had stable and treated brain metastases at baseline.

Tiragolumab/Atezolizumab Shows Early First-in-Human Efficacy in Frontline PD-L1+ NSCLC

June 24th 2020

Tiragolumab in combination with atezolizumab (Tecentriq) demonstrated early clinical activity and was found to be well tolerated in patients with advanced solid tumors, including those with metastatic non–small cell lung cancer who were PD-L1 positive and had not received prior checkpoint inhibition.

Dr. Horn on Updated IMpower133 Data in Small Cell Lung Cancer

June 23rd 2020

Leora Horn, MD, MSc, discusses data from an updated analysis of the phase 3 IMpower133 trial, which examined the first-line combination of atezolizumab (Tecentriq), carboplatin, and etoposide in small cell lung cancer.

Utility of Minimally Invasive Plasma-Based NGS Expands in NSCLC

June 23rd 2020

Plasma-based next-generation sequencing continues to offer a minimally invasive, highly specific modality to identify patients with actionable alterations in non–small cell lung cancer.

ctDNA Clearance Shows Correlation With PFS Improvement in EGFR+/MET+ NSCLC

June 23rd 2020

Circulating tumor DNA clearance of EGFR mutation may be predictive of prolonged progression-free survival for patients with EGFR-mutant, MET-amplified non–small cell lung cancer with detectable ctDNA at baseline.

Rapid Readouts: Three-Year Update From CheckMate 227, Part 1

June 23rd 2020